

Sub C1

7. (New) A method of treating hepatocellular carcinoma, said method comprising administering to a patient docetaxel in an amount sufficient to treat said hepatocellular carcinoma.

8. The method of claim 7, wherein said hepatocellular carcinoma is a fibrolamellar variant.

9. (New) The method of claim 7, wherein said hepatocellular carcinoma is a mixed hepatocellular cholangiocarcinoma.

10. (New) The method of claim 7, wherein administration is intraperitoneal, subcutaneous, intravenous, intramuscular, or intrasternal.

11. (New) The method of claim 10, wherein administration is intravenous.

12. (New) The method of claim 11, wherein administration is by intravenous infusion.

13. (New) The method of claim 7, further comprising treating with at least one chemotherapeutic agent or antineoplastic drug other than docetaxel.

14. (New) The method of claim 7, further comprising treating with at least one biological response modifier.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

15. (New) The method of claim 7, further comprising treating with immunotherapy, radiotherapy, or both.

16. (New) The method of claim 7, wherein the patient is a human.

17. (New) The method of claim 16, wherein said method comprises administering docetaxel in at least one dose of from 50 to 150 mg/m<sup>2</sup>.

18. (New) The method of claim 17, wherein said method comprises administering docetaxel in at least one dose of from 60 to 100 mg/m<sup>2</sup>.

19. (New) The method of claim 17, wherein said method comprises administering docetaxel or a hydrate of docetaxel in at least one dose of 100 mg/m<sup>2</sup>.

20. (New) The method of claim 7, wherein said method comprises weekly administration until the desired therapeutic effect is obtained.

21. (New) The method of claim 7, wherein said method comprises administration every three weeks until the desired therapeutic effect is obtained.

22. (New) The method of claim 21, wherein said method comprises intravenously infusing docetaxel at a dose of 100 mg/m<sup>2</sup> over 1 hour every three weeks until the desired therapeutic effect is obtained.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com